Scholarlink

<p>This is a summary of the original article “Economic Benefit of Aflibercept 8&#xa0;mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”. Aflibercept 8&#xa0;mg and faricimab are medications given by injections into the eye for treating the eye diseases neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Comparing costs of these medications is important for patients, healthcare practitioners, and the people who pay for medications (payers). This research used an economic model to compare the estimated costs of aflibercept 8&#xa0;mg and faricimab over 5&#xa0;years in the United States, based on numbers of injections given in clinical trials. The analysis indicated that the lower number of injections needed for aflibercept 8&#xa0;mg would lead to lower costs compared with faricimab for patients with nAMD or DME, which could benefit patients, healthcare providers, and payers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Andreas Kuznik,
  • Anna Coughlan,
  • Amy Pinsent,
  • Hector Toro-Diaz,
  • Steven Sherman,
  • Nimesh A. Patel

摘要

This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”. Aflibercept 8 mg and faricimab are medications given by injections into the eye for treating the eye diseases neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Comparing costs of these medications is important for patients, healthcare practitioners, and the people who pay for medications (payers). This research used an economic model to compare the estimated costs of aflibercept 8 mg and faricimab over 5 years in the United States, based on numbers of injections given in clinical trials. The analysis indicated that the lower number of injections needed for aflibercept 8 mg would lead to lower costs compared with faricimab for patients with nAMD or DME, which could benefit patients, healthcare providers, and payers.